SecBot SecBot
SECBOTREPLAY Home › Report › RGEN

RGEN · Repligen reported Q2 2026 revenue of $204M (+12% YoY) and adjusted EPS…

REPLIGEN CORP · 8-K filed Jul 28, 2026 at 07:13 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 28, 2026 at 07:13 ET

Repligen reported Q2 2026 revenue of $204M (+12% YoY) and adjusted EPS of $0.54, beating consensus by 20.4%. The company raised full-year 2026 guidance for organic revenue growth to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, while also announcing a definitive agreement to acquire BioLife Solutions, a strategic move into cell therapy consumables.

  • Q2 2026 revenue $204M, +12% reported and +13% organic YoY
  • Adjusted EPS $0.54 vs consensus $0.45 (beat by 20.4%)
  • GAAP EPS $0.09 vs $0.26 YoY due to acquisition/amortization costs
  • Raised FY26 guidance: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access